Tag: NYSE:PFE

Finance

Healthcare Active Runners: Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Bristol-Myers Squibb (NYSE:BMY)

Three years after Pfizer Inc. (NYSE:PFE) announced more than 1,000 layoffs that Gov. Dannel P. Malloy at the time called “terrible news,” the pharmaceutical company and the state said Wednesday they’ve come up with new uses for the Groton site. Malloy and top officials of his administration and Pfizer Inc (NYSE:PFE) said two vacant buildings on the company’s campus will be used for bioscience research … Continue reading Healthcare Active Runners: Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Bristol-Myers Squibb (NYSE:BMY)

Jayne Crisman
Finance

Active STocks at NYSE; AT&T Inc. (NYSE:T), Petroleo Brasileiro Petrobras) (NYSE:PBR), Pfizer Inc. (NYSE:PFE)

U.S. telecom giant AT&T Inc. (NYSE:T) has announced a new repurchase program of up to 300 million shares. The buyback represents nearly 6% of the company’s outstanding shares and does not have any expiration date. AT&T Inc. (NYSE:T) stock performance was 0.06% in last session and finished the day at $35.09. Traded volume was 28.78million shares in the last session and the average volume of … Continue reading Active STocks at NYSE; AT&T Inc. (NYSE:T), Petroleo Brasileiro Petrobras) (NYSE:PBR), Pfizer Inc. (NYSE:PFE)

Mark DeFrance
Finance

Healthcare Active Runners: Merck & Co. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), Ariad Pharmaceuticals (NASDAQ:ARIA)

Merck & Co., Inc. (NYSE:MRK) is getting close to conducting phase 3 trials for a combination treatment for Hepatitis C, which could potentially rejuvenate the pharmaceutical giant’s revenue growth. The clinical data for a combination of drugs MK-5172 and MK-8742 has showed high cure rates among patients with genotype 1 of the disease, and this has encouraged Merck to move to phase 3 trials. Merck … Continue reading Healthcare Active Runners: Merck & Co. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), Ariad Pharmaceuticals (NASDAQ:ARIA)

Kevin Long
Finance

Healthcare Active Runners: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Inovio Pharmaceuticals (NYSEMKT:INO), Johnson & Johnson (NYSE:JNJ)

Pfizer Inc. (NYSE:PFE) announced encouraging top-line data from a phase IIIb study evaluating Genotropin for increasing height in small-for-gestational-age (SGA) children aged between 24 and 30 months. Pfizer Inc. (NYSE:PFE) stock performance was -0.25% in last session and finished the day at $32.10. Traded volume was 27.74million shares in the last session and the average volume of the stock remained 26.63million shares. The beta of … Continue reading Healthcare Active Runners: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Inovio Pharmaceuticals (NYSEMKT:INO), Johnson & Johnson (NYSE:JNJ)

Jayne Crisman
Finance

NYSE Active Stocks: Oracle Corporation (NYSE:ORCL), AT&T Inc. (NYSE:T), Pfizer Inc. (NYSE:PFE), Verizon Communications Inc. (NYSE:VZ)

Grupo Farmacos Especializados Determined Oracle Corporation (NYSE:ORCL) Engineered Systems to Be the Most Efficient, Cost-Effective Solution for Maintaining Business Growth Oracle Corporation (NYSE:ORCL) stock performance was 1.77% in last session and finished the day at $39.08. Traded volume was 31.36 million shares in the last session and the average volume of the stock remained 16.07 million shares. The beta of the stock remained 1.28. Oracle … Continue reading NYSE Active Stocks: Oracle Corporation (NYSE:ORCL), AT&T Inc. (NYSE:T), Pfizer Inc. (NYSE:PFE), Verizon Communications Inc. (NYSE:VZ)

Colin Pettis
Finance

Healthcare Most Active: Pfizer Inc. (NYSE:PFE), Bristol-Myers Squibb (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Pfizer Inc. (NYSE:PFE) announced that PROFILE 1014, a phase 3 study of anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib), met its primary objective of significantly prolonging progression-free survival (PFS) in previously untreated patients with ALK-positive advanced non-squamous non-small cell lung cancer (NSCLC) when compared to standard platinum-based chemotherapy regimens. Pfizer Inc. (NYSE:PFE) stock performance was 1.13% in last session and finished the day at $32.18. … Continue reading Healthcare Most Active: Pfizer Inc. (NYSE:PFE), Bristol-Myers Squibb (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Colin Pettis